Competition refresher magazine
Competition refresher magazine published this article page no 33 donanemab a monoclonal antibody has gained attention as a recently approved drug for alzheimers disease. monoclonal antibodies are designed to target specific molecules in the body and in the case of alzheimers donanemab specifically targets amyloid beta protein plaques which are considered a defining feature of the disease competition refresher magazine subscription.
No comments:
Post a Comment